Stockreport

HUTCHMED Announces Positive Topline Results of Phase III Part of ESLIM-02 Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China

HUTCHMED (China) Limited - American Depositary Shares  (HCM) 
NASDAQ:AMEX Investor Relations: chi-med.com/investors/information-for-shareholders
PDF — Delivers rapid, durable responses in wAIHA, the more common form of this potentially life-threatening disease —  HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Jan. [Read more]